217 related articles for article (PubMed ID: 38260279)
1. Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression.
Shaw TI; Wagner J; Tian L; Wickman E; Poudel S; Wang J; Paul R; Koo SC; Lu M; Sheppard H; Fan Y; O'Neil F; Lau CC; Zhou X; Zhang J; Gottschalk S
Res Sq; 2024 Jan; ():. PubMed ID: 38260279
[TBL] [Abstract][Full Text] [Related]
2. Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression.
Shaw TI; Wagner J; Tian L; Wickman E; Poudel S; Wang J; Paul R; Koo SC; Lu M; Sheppard H; Fan Y; O'Neill FH; Lau CC; Zhou X; Zhang J; Gottschalk S
Nat Commun; 2024 May; 15(1):3732. PubMed ID: 38702309
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin.
Wagner J; Wickman E; Shaw TI; Anido AA; Langfitt D; Zhang J; Porter SN; Pruett-Miller SM; Tillman H; Krenciute G; Gottschalk S
Cancer Immunol Res; 2021 Mar; 9(3):279-290. PubMed ID: 33355188
[TBL] [Abstract][Full Text] [Related]
4. CAR-T Therapy Targets Extra Domain B of Fibronectin Positive Solid Tumor Cells.
Tang J; Liu N; Zhu Y; Li Y; Zhao X
Immunol Invest; 2023 Nov; 52(8):985-996. PubMed ID: 37815216
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
6. CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B.
Zhang Z; Liu C; Yang Z; Yin H
Cells; 2022 Sep; 11(18):. PubMed ID: 36139437
[TBL] [Abstract][Full Text] [Related]
7. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
[TBL] [Abstract][Full Text] [Related]
8. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z; Liu C; Wang M; Sun R; Yang Z; Hua Z; Wu Y; Wu M; Wang H; Qiu W; Yin H; Yang M
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586774
[TBL] [Abstract][Full Text] [Related]
9. Identification of five mouse mu-opioid receptor (MOR) gene (Oprm1) splice variants containing a newly identified alternatively spliced exon.
Doyle GA; Sheng XR; Lin SS; Press DM; Grice DE; Buono RJ; Ferraro TN; Berrettini WH
Gene; 2007 Jun; 395(1-2):98-107. PubMed ID: 17398041
[TBL] [Abstract][Full Text] [Related]
10. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
[TBL] [Abstract][Full Text] [Related]
11. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Foster JB; Griffin C; Rokita JL; Stern A; Brimley C; Rathi K; Lane MV; Buongervino SN; Smith T; Madsen PJ; Martinez D; Delaidelli A; Sorensen PH; Wechsler-Reya RJ; Karikó K; Storm PB; Barrett DM; Resnick AC; Maris JM; Bosse KR
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36167467
[TBL] [Abstract][Full Text] [Related]
12. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
13. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.
Gardina PJ; Clark TA; Shimada B; Staples MK; Yang Q; Veitch J; Schweitzer A; Awad T; Sugnet C; Dee S; Davies C; Williams A; Turpaz Y
BMC Genomics; 2006 Dec; 7():325. PubMed ID: 17192196
[TBL] [Abstract][Full Text] [Related]
14. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues.
Poola I; Speirs V
J Steroid Biochem Mol Biol; 2001 Nov; 78(5):459-69. PubMed ID: 11738556
[TBL] [Abstract][Full Text] [Related]
15. Identification of Cell Surface Targets for CAR T Cell Immunotherapy.
DeLucia DC; Lee JK
Methods Mol Biol; 2020; 2097():45-54. PubMed ID: 31776917
[TBL] [Abstract][Full Text] [Related]
16. CAR-T cells for pediatric brain tumors: Present and future.
Leruste A; Beccaria K; Doz F
Bull Cancer; 2021 Oct; 108(10S):S109-S116. PubMed ID: 34920793
[TBL] [Abstract][Full Text] [Related]
17. GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells.
Ibanez J; Hebbar N; Thanekar U; Yi Z; Houke H; Ward M; Nevitt C; Tian L; Mack SC; Sheppard H; Chiang J; Velasquez MP; Krenciute G
Cell Rep Med; 2023 Nov; 4(11):101297. PubMed ID: 37992682
[TBL] [Abstract][Full Text] [Related]
18. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
19. Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
Nguyen DT; Liu R; Ogando-Rivas E; Pepe A; Pedro D; Qdaisat S; Nguyen NTY; Lavrador JM; Golde GR; Smolchek RA; Ligon J; Jin L; Tao H; Webber A; Phillpot S; Mitchell DA; Sayour EJ; Huang J; Castillo P; Gregory Sawyer W
Acta Biomater; 2023 Dec; 172():466-479. PubMed ID: 37788737
[TBL] [Abstract][Full Text] [Related]
20. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Martín-Otal C; Lasarte-Cia A; Serrano D; Casares N; Conde E; Navarro F; Sánchez-Moreno I; Gorraiz M; Sarrión P; Calvo A; De Andrea CE; Echeveste J; Vilas A; Rodriguez-Madoz JR; San Miguel J; Prosper F; Hervas-Stubbs S; Lasarte JJ; Lozano T
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35918123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
